164 related articles for article (PubMed ID: 31295074)
1. Cost-utility of a biofilm-disrupting gel versus standard of care in chronic wounds: a Markov microsimulation model based on a randomised controlled trial.
Carter MJ; Myntti MF
J Wound Care; 2019 Jul; 28(Sup7):S24-S38. PubMed ID: 31295074
[TBL] [Abstract][Full Text] [Related]
2. Dehydrated human amnion and chorion allograft versus standard of care alone in treatment of Wagner 1 diabetic foot ulcers: a trial-based health economics study.
Carter MJ
J Med Econ; 2020 Nov; 23(11):1273-1283. PubMed ID: 32729342
[TBL] [Abstract][Full Text] [Related]
3. Early versus deferred endovenous ablation of superficial venous reflux in patients with venous ulceration: the EVRA RCT.
Gohel MS; Heatley F; Liu X; Bradbury A; Bulbulia R; Cullum N; Epstein DM; Nyamekye I; Poskitt KR; Renton S; Warwick J; Davies AH
Health Technol Assess; 2019 May; 23(24):1-96. PubMed ID: 31140402
[TBL] [Abstract][Full Text] [Related]
4. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
5. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
6. Clinical Assessment of a Biofilm-disrupting Agent for the Management of Chronic Wounds Compared With Standard of Care: A Therapeutic Approach.
Kim D; Namen Ii W; Moore J; Buchanan M; Hayes V; Myntti MF; Hakaim A
Wounds; 2018 May; 30(5):120-130. PubMed ID: 29521641
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of PHMB & betaine wound bed preparation compared with standard care in venous leg ulcers: A cost-utility analysis in the United Kingdom.
Cooper DM; Bojke C; Ghosh P
J Tissue Viability; 2023 May; 32(2):262-269. PubMed ID: 36990897
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of negative pressure wound therapy in patients with many comorbidities and severe wounds of various etiology.
Driver VR; Eckert KA; Carter MJ; French MA
Wound Repair Regen; 2016 Nov; 24(6):1041-1058. PubMed ID: 27669667
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
10. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
11. Economic aspects of biofilm-based wound care in diabetic foot ulcers.
Wolcott R
J Wound Care; 2015 May; 24(5):189-90, 192-4. PubMed ID: 25970755
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of a novel soluble beta-glucan gel.
Cutting KF
J Wound Care; 2017 May; 26(5):228-234. PubMed ID: 28475444
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Novel Macrophage-Regulating Treatment for Wound Healing in Patients With Diabetic Foot Ulcers From the Taiwan Health Care Sector Perspective.
Su HY; Yang CY; Ou HT; Chen SG; Chen JC; Ho HJ; Kuo S
JAMA Netw Open; 2023 Jan; 6(1):e2250639. PubMed ID: 36633847
[TBL] [Abstract][Full Text] [Related]
14. Cost-Utility Analysis of Negative Pressure Wound Therapy Compared With Traditional Wound Care in the Treatment of Diabetic Foot Ulcers in Iran.
Alipour V; Rezapour A; Ebrahimi M; Arabloo J
Wounds; 2021 Feb; 33(2):50-56. PubMed ID: 33591928
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of adding clostridial collagenase ointment to selective debridement in individuals with stage IV pressure ulcers.
Carter MJ; Gilligan AM; Waycaster CR; Schaum K; Fife CE
J Med Econ; 2017 Mar; 20(3):253-265. PubMed ID: 27774840
[TBL] [Abstract][Full Text] [Related]
16. Cost Effectiveness of Becaplermin Gel on Wound Closure for the Treatment of Pressure Injuries.
Gilligan AM; Waycaster CR; Milne CT
Wounds; 2018 Jun; 30(6):197-204. PubMed ID: 29809161
[TBL] [Abstract][Full Text] [Related]
17. A Cost-Effectiveness Analysis Comparing Single-use and Traditional Negative Pressure Wound Therapy to Treat Chronic Venous and Diabetic Foot Ulcers.
Kirsner RS; Delhougne G; Searle RJ
Wound Manag Prev; 2020 Mar; 66(3):30-36. PubMed ID: 32294054
[TBL] [Abstract][Full Text] [Related]
18. Health economic burden that different wound types impose on the UK's National Health Service.
Guest JF; Ayoub N; McIlwraith T; Uchegbu I; Gerrish A; Weidlich D; Vowden K; Vowden P
Int Wound J; 2017 Apr; 14(2):322-330. PubMed ID: 27229943
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
20. Antibiotics and antiseptics for venous leg ulcers.
O'Meara S; Al-Kurdi D; Ologun Y; Ovington LG; Martyn-St James M; Richardson R
Cochrane Database Syst Rev; 2013 Dec; (12):CD003557. PubMed ID: 24363048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
